Exicure (XCUR) Competitors $2.74 -0.25 (-8.23%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock XCUR vs. GOSS, JATT, SPRB, BHST, and ANVSShould you buy Exicure stock or one of its competitors? MarketBeat compares Exicure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exicure include Gossamer Bio (GOSS), JATT Acquisition (JATT), Spruce Biosciences (SPRB), BioHarvest Sciences (BHST), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical products" industry. XCUR vs. GOSSXCUR vs. JATTXCUR vs. SPRBXCUR vs. BHSTXCUR vs. ANVSHow does Exicure compare to Gossamer Bio?Exicure (NASDAQ:XCUR) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation. Do analysts rate XCUR or GOSS? Gossamer Bio has a consensus price target of $5.00, indicating a potential upside of 2,388.80%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20 Do insiders & institutionals believe in XCUR or GOSS? 42.8% of Exicure shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 7.2% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is XCUR or GOSS more profitable? Exicure has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -138.71% -62.76% Gossamer Bio -324.82%N/A -96.10% Which has more risk and volatility, XCUR or GOSS? Exicure has a beta of 3.62, suggesting that its stock price is 262% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.15, suggesting that its stock price is 115% more volatile than the broader market. Does the media favor XCUR or GOSS? In the previous week, Gossamer Bio had 34 more articles in the media than Exicure. MarketBeat recorded 35 mentions for Gossamer Bio and 1 mentions for Exicure. Gossamer Bio's average media sentiment score of -0.03 beat Exicure's score of -0.71 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Gossamer Bio 0 Very Positive mention(s) 1 Positive mention(s) 33 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, XCUR or GOSS? Exicure has higher earnings, but lower revenue than Gossamer Bio. Exicure is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicureN/AN/A-$4.95M-$0.77N/AGossamer Bio$48.47M0.97-$170.37M-$0.79N/A SummaryGossamer Bio beats Exicure on 9 of the 15 factors compared between the two stocks.How does Exicure compare to JATT Acquisition?Exicure (NASDAQ:XCUR) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation. Is XCUR or JATT more profitable? JATT Acquisition's return on equity of -49.58% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -138.71% -62.76% JATT Acquisition N/A -49.58%2.84% Do analysts rate XCUR or JATT? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor XCUR or JATT? In the previous week, JATT Acquisition had 1 more articles in the media than Exicure. MarketBeat recorded 2 mentions for JATT Acquisition and 1 mentions for Exicure. JATT Acquisition's average media sentiment score of 0.00 beat Exicure's score of -0.71 indicating that JATT Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative JATT Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of XCUR or JATT? 42.8% of Exicure shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 20.0% of JATT Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has stronger valuation & earnings, XCUR or JATT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicureN/AN/A-$4.95M-$0.77N/AJATT AcquisitionN/AN/A$6.85MN/AN/A SummaryJATT Acquisition beats Exicure on 6 of the 8 factors compared between the two stocks.How does Exicure compare to Spruce Biosciences?Spruce Biosciences (NASDAQ:SPRB) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations. Which has more volatility and risk, SPRB or XCUR? Spruce Biosciences has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market. Comparatively, Exicure has a beta of 3.62, indicating that its stock price is 262% more volatile than the broader market. Do analysts prefer SPRB or XCUR? Spruce Biosciences presently has a consensus target price of $186.60, suggesting a potential upside of 254.08%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Spruce Biosciences is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do insiders & institutionals hold more shares of SPRB or XCUR? 91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is SPRB or XCUR more profitable? Exicure's return on equity of -138.71% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Spruce BiosciencesN/A -155.40% -101.67% Exicure N/A -138.71%-62.76% Does the media prefer SPRB or XCUR? In the previous week, Spruce Biosciences had 1 more articles in the media than Exicure. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for Exicure. Spruce Biosciences' average media sentiment score of -0.54 beat Exicure's score of -0.71 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Exicure 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Which has stronger valuation and earnings, SPRB or XCUR? Exicure has lower revenue, but higher earnings than Spruce Biosciences. Exicure is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M14.70-$38.97M-$36.60N/AExicureN/AN/A-$4.95M-$0.77N/A SummarySpruce Biosciences beats Exicure on 8 of the 14 factors compared between the two stocks.How does Exicure compare to BioHarvest Sciences?BioHarvest Sciences (NASDAQ:BHST) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings. Which has more risk & volatility, BHST or XCUR? BioHarvest Sciences has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Exicure has a beta of 3.62, meaning that its stock price is 262% more volatile than the broader market. Do insiders & institutionals believe in BHST or XCUR? 42.8% of Exicure shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, BHST or XCUR? Exicure has lower revenue, but higher earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioHarvest Sciences$34.51M2.17-$11.14M-$0.59N/AExicureN/AN/A-$4.95M-$0.77N/A Does the media favor BHST or XCUR? In the previous week, BioHarvest Sciences had 14 more articles in the media than Exicure. MarketBeat recorded 15 mentions for BioHarvest Sciences and 1 mentions for Exicure. BioHarvest Sciences' average media sentiment score of 0.09 beat Exicure's score of -0.71 indicating that BioHarvest Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioHarvest Sciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Exicure 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Is BHST or XCUR more profitable? Exicure has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets BioHarvest Sciences-32.54% -76.03% -25.30% Exicure N/A -138.71%-62.76% Do analysts recommend BHST or XCUR? BioHarvest Sciences currently has a consensus target price of $10.00, suggesting a potential upside of 161.78%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioHarvest Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryBioHarvest Sciences beats Exicure on 9 of the 15 factors compared between the two stocks.How does Exicure compare to Annovis Bio?Annovis Bio (NYSE:ANVS) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends. Which has more volatility & risk, ANVS or XCUR? Annovis Bio has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Exicure has a beta of 3.62, indicating that its stock price is 262% more volatile than the broader market. Do analysts rate ANVS or XCUR? Annovis Bio currently has a consensus price target of $13.50, suggesting a potential upside of 526.45%. Given Annovis Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is ANVS or XCUR more profitable? Exicure's return on equity of -138.71% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -318.08% -215.47% Exicure N/A -138.71%-62.76% Which has higher earnings and valuation, ANVS or XCUR? Exicure is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$28.85M-$1.71N/AExicureN/AN/A-$4.95M-$0.77N/A Do institutionals & insiders believe in ANVS or XCUR? 15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 52.8% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media favor ANVS or XCUR? In the previous week, Annovis Bio had 5 more articles in the media than Exicure. MarketBeat recorded 6 mentions for Annovis Bio and 1 mentions for Exicure. Annovis Bio's average media sentiment score of -0.39 beat Exicure's score of -0.71 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exicure 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative SummaryExicure beats Annovis Bio on 7 of the 13 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition ExportMetricExicureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.59M$3.36B$6.34B$12.29BDividend YieldN/A2.32%2.80%5.36%P/E Ratio-3.5819.0120.9225.47Price / SalesN/A278.84521.1573.36Price / CashN/A125.3543.1855.00Price / Book4.456.909.987.00Net Income-$4.95M$24.23M$3.55B$335.16M7 Day Performance-13.21%0.58%0.40%-0.29%1 Month Performance-26.60%-0.61%-0.02%1.18%1 Year Performance-73.32%63.26%34.94%34.78% Exicure Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure0.642 of 5 stars$2.76-7.7%N/A-70.7%$17.59MN/AN/A50Gap DownGOSSGossamer Bio2.918 of 5 stars$0.35+1.9%$5.43+1,464.4%-81.8%$80.97M$48.47MN/A180Trending NewsEarnings ReportAnalyst DowngradeGap UpJATTJATT AcquisitionN/A$10.33-1.8%N/A+871.4%$80.57MN/AN/A3News CoverageSPRBSpruce Biosciences2.3417 of 5 stars$57.46+1.4%$190.60+231.7%+958.2%$78.90M$4.91MN/A20BHSTBioHarvest Sciences2.6528 of 5 stars$4.01+4.4%$10.00+149.4%-40.4%$78.62M$34.51MN/AN/AEarnings ReportAnalyst RevisionGap Down Related Companies and Tools Related Companies Gossamer Bio Alternatives JATT Acquisition Alternatives Spruce Biosciences Alternatives BioHarvest Sciences Alternatives Annovis Bio Alternatives XBiotech Alternatives Gain Therapeutics Alternatives ImmuCell Alternatives Seres Therapeutics Alternatives Rallybio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
